Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Cash (2016 - 2025)

Ani Pharmaceuticals' Change in Cash history spans 16 years, with the latest figure at $23.0 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 18778.86% year-over-year to $23.0 million; the TTM value through Dec 2025 reached $140.7 million, up 284.62%, while the annual FY2025 figure was $140.7 million, 284.62% up from the prior year.
  • Change in Cash for Q4 2025 was $23.0 million at Ani Pharmaceuticals, down from $44.8 million in the prior quarter.
  • Across five years, Change in Cash topped out at $94.0 million in Q2 2023 and bottomed at -$95.1 million in Q3 2024.
  • The 5-year median for Change in Cash is $9.5 million (2024), against an average of $13.6 million.
  • The largest annual shift saw Change in Cash plummeted 1567.69% in 2022 before it soared 18778.86% in 2025.
  • A 5-year view of Change in Cash shows it stood at $85.0 million in 2021, then tumbled by 109.47% to -$8.0 million in 2022, then soared by 448.36% to $28.0 million in 2023, then crashed by 100.44% to -$123000.0 in 2024, then skyrocketed by 18778.86% to $23.0 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Change in Cash are $23.0 million (Q4 2025), $44.8 million (Q3 2025), and $68.0 million (Q2 2025).